IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:	Group Art Unit: 1617		
McDonald, G. et al.) Examiner: Jiang, S.		
Serial No.: 09/753,814)		
Filed: January 3, 2001)		
For: METHOD OF LONG-TERM TREATMENT OF GRAFT-VERSUS- HOST DISEASE USING TOPICAL ACTIVE CORTICOSTEROIDS)))		

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449 and copies are enclosed for the convenience of the Examiner.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

	CERTIFICATE OF MAILING
	(37 C.F.R. §1.8a)
hereby certify that this paper (along with any refer late shown below with sufficient postage as First C	rred to as being attached or enclosed) is being deposited with the United States Postal Service on the Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.
	Michele DeRosso Name of Person Mailing Paper

Information Disclosure Statement Filing Provision: This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application filed under § 1.53(d); or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required. However, if the undersigned is in error in this regard, Applicant respectfully requests that the \square Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR §1.17(p) to the deposit account referenced below. П However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required. This IDS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action 冈 on the merits, but before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311. 冈 The fee due under 37 CFR § 1.17(p) is submitted herewith. П A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below. This IDS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311, but before payment of the issue fee. A statement under 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted herewith.

STATEMENT UNDER 37 CFR § 1.97(e):	
Each item contained in this IDS was first cited in any communication from a f	oreign patent
office in a counterpart foreign application not more than three months prior to the filir	
No item contained in this IDS was cited in a communication from a foreign pa	
counterpart foreign application, and, to the knowledge of the person signing this states	
making reasonable inquiry, no item of information contained in this IDS was known to	
individual designated in 37 CFR § 1.56(c) more than three months prior to the filing o	-
PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:	
A check in the amount of \$180.00 is enclosed for the above fee(s).	
Please charge to Deposit Account No. 12-2475 for the above fee(s).	
The Commissioner is authorized to charge any fees required by the filing of these paper	ers, and to
credit any overpayment to Lyon & Lyon's Deposit Account No. 12-2475.	·
Respectfully submitted,	
LYON & LYON LLP	
Dated: 4/16/01 By: Charles M. Duff	-
Charles M. Doyle Reg. No. 39,175	
1/10 1/10 1/10 1/10 1/10 1/10 1/10 1/10	,

LYON & LYON LLP 633 W. Fifth Street, Suite 4700 Los Angeles, CA 90071 (914) 681-8851

22249

WP-19909.1

Please acknowledge receipt of the following by affixing hereon the Patent and Trademark Office date stamp and returning this card to our office.

Applicant:

McDonald, G., et al.

Serial No.:

09/753,814

For:

METHOD OF LONG-TERM TREATMENT OF GRAFT-VERSUS-HOST

DISEASE USING TOPICAL ACTIVE CORTICOSTEROIDS

Filed:

January 3, 2001

TRANSMITTAL

Attorney(s):

Charles M. Doyle, Esq. 259/284

Docket No.:
Date of Deposit:

April 16, 2002

Enclosure(s):

Transmittal Form with Certificate of Mailing; Information Disclosure Statement; PTO Form 1449 with copies of Prior Art References; Fee Transmittal Form;

Lyon & Lyon check no. 15605 in the amount of \$180.00; Return Postcard.



Charles M. Doyle, Esq. Lyon & Lyon, LLP 633 West Fifth Street, Suite 4700 Los Angeles, California 90071-2066

FORM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) ATTY. DOCK' NO. SERIAL NO. 09/753,814 APPLICANT: McDonald, George B. and Nicholas Stergiopoulos FILING DATE: GROUP: January 3, 2001 1617

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
 	AA_	5,403,833	04/04/95	Calme	514	171	
- T	AB						
	AC						
	AD						
	AE		_				

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANS YES	LATION NO
	AI							
	AJ							
	AK	·						

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
AL	Storb, R. And Thomas, D., "Graft-versus-Host Disease in Dog and Man: The Seattle Experience", 1985, <i>Immunological Rev.</i> 88:216-238.
AM	Storb, R. et al., "What Role for Prednisone in Prevention of Acute Graft-versus-Host Disease in Patients Undergoing Marrow Transplants?", 1990, Blood 76(5):1037-1045.
AN	Sayer, H.G. et al., "Increased Risk of Infection in Marrow Transplant Patients Receiving Methylprednisolone for Graft-versus-Host Disease Prevention", 1994, Blood 84(4):1328-1332.
AO	Deeg, H.J. et al., "Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial",
AP	Nash, R.A. and Storb, R., "Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL", 1996, Curr. Op. Immunol. 8(5):674-680.
AQ	Chao, N.J., "Pharmacology and Use of Immunosuppressive Agents After Hematopoietic Cell Transplantation", in Hematopoietic Cell Transplantation, Thomas, E.D. et al. (eds.), 2 nd Ed. pp. 176-185. Blackwell Scientific Publications, Boston, MA.
AR	Singh, C. and McDonald, G.B., "Intestinal and Hepatic Complications of Bone Marrow and Stem Cell Transplantation", in Gastrointestinal Emergencies, Taylor, M.B. et al., eds., Williams & Wilkins, Baltimore (997).
AS	Kernan, N.A., T-Cell Depletion for the Prevention of Graft-Versus-Host Disease", in <u>Hematopoietic Cell Transplantation</u> , Thomas, E.D. et al. (eds.), 2 nd Ed. pp. 186-196. Blackwell Scientific Publications, Boston, MA.
AT	Ferrara, J.L.M. and Antin, J. H., "The Pathophysiology of Graft-Versus-Host Disease", in Hematopoietic Cell Transplantation, Thomas, E.D. et al. (eds.), 2 nd Ed. pp. 305-315. Blackwell Scientific Publications, Boston, MA.

EXAMINER: Jiang, S.	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether of Draw line through citation if not in conformance and no	or not citation is in conformance with MPEP 609; ot considered. Include a copy of this form with next

communication to applicant

Information Disclosure Statement – Section 9 PTO-1449